Geoffrey Y. Ku, MD, discusses the rationale to evaluate zanidatamab in combination with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma.
Geoffrey Y. Ku, MD, medical oncologist, head, Esophagogastric Section, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the rationale to evaluate zanidatamab in combination with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma (GEA).
In the phase 1 ZW25-101 trial (NCT02892123), zanidatamab, a bispecific, IgG1-like antibody, demonstrated durable responses and good tolerability when used as monotherapy in patients with heavily pretreated advanced or metastatic HER2-expressing GEA, Ku explains. The confirmed overall response rate was 33% among 35 patients in this population, and the median duration of response was 6 months.
These results served as the basis for the ongoing phase 2 ZWI-ZW25-201 trial (NCT03929666), which is evaluating zanidatamab in combination with physician’s choice of standard frontline chemotherapy in patients with unresectable, locally advanced, or metastatic HER2-expressing GEA, Ku concludes.